Effective Salvage Therapy for Refractory Disseminated Breast Cancer with 5-Fluorouracil and High-Dose Continuous Infusion Folinic Acid
Treatment options are limited for patients with disseminated carcinoma of the breast whose disease has progressed after therapy with standard chemotherapeutic programs (1). In fact, the usefulness of testing investigational agents in those breast cancer patients who have been heavily pretreated, (two or more prior regimens), has been questioned recently (2). Thus, the discovery of effective therapy for this patient population is of considerable interest.
KeywordsBreast Cancer Metastatic Breast Cancer Advanced Breast Cancer Objective Response Rate Folinic Acid
Unable to display preview. Download preview PDF.
- 1.I. C. Henderson, D. F. Hayes, S. Come, J. R. Harris, and G. Canellos, New agents and new medical treatments for advanced breast cancer, Sem. in Onc. 14:34 (1987).Google Scholar
- 2.E. Estey, D. Hoth, R. Simon, S. Marsoni, B. Leyland- Jones, and R. Wittes, Therapeutic response in phase I trials of antineoplastic agents, Cancer Treat. Rep. 70: 1105 (1986).Google Scholar
- 4.M. B. Yin, S. F. Zakrzewski, and M. T. Hakala, Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil, Mol. Pharmacol. 23: 190 (1983).Google Scholar
- 6.J. H. Doroshow, M. Bertrand, E. Newman, P. Multhauf, L. Leong, D. Blayney, D. Goldberg, K. Margolin, B. Carr, S. Akman, and G. Metter, Preliminary analysis of a randomized comparison of 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer, NCI Monogr. 5: 171 (1987).PubMedGoogle Scholar
- 8.J. R. Harris, S. Hellman, G. P. Canellos, and B. Fisher, Cancer of the breast, in: “Cancer: Principles and Practice of Oncology,” V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg, eds., J. B. Lippincott Co., Philadelphia (1985).Google Scholar